Avexitide

Post-bariatric hypoglycemia is in a sense a GLP-1 problem in reverse: after bariatric surgery an exaggerated GLP-1 response drives excessive insulin secretion, and blood glucose crashes after meals. Blocking the GLP-1 receptor rather than stimulating it is therefore the rational treatment, which is what makes avexitide an unusual entry in a field otherwise built on agonism.

The pivotal Phase 3 LUCIDITY trial met its primary and all key secondary endpoints, with a 55% reduction in severe hypoglycemic events. The FDA has granted Breakthrough Therapy Designation in both post-bariatric hypoglycemia and congenital hyperinsulinism, plus Orphan Drug and Rare Pediatric Disease designations. Amylyx acquired it from Eiger BioPharmaceuticals in 2024 and has signalled an FDA filing.

// COMPETITIVE GLP-1 RECEPTOR ANTAGONISM

Avexitide is exendin(9-39), the truncated form of exendin-4 missing the first eight N-terminal residues. That truncation removes the receptor-activating portion while retaining binding affinity, so the peptide occupies the GLP-1 receptor on pancreatic beta cells without triggering it — competitively displacing endogenous GLP-1 and blunting the exaggerated insulin response that causes the hypoglycemia.

// GLUCOSE STABILISATION

By curbing inappropriate post-prandial insulin secretion rather than adding glucose, it addresses the mechanism rather than the symptom, which is why effects concentrate on the severe (Level 2 and 3) events that define the condition's burden.

Investigational, Phase 3 complete (LUCIDITY) with FDA filing signalled; not yet approved. Formula independently computed from the published sequence and matches the published C149H234N40O47S exactly. Note that vendor listings often quote an acetate salt form with a different molecular weight.